• Therapeutically relevant—select from the most diverse collection of clinically relevant kinase mutants
  • Validation-qualified—all mutations confirmed by mass spectrometry and validated using control inhibitors
  • Ready-to-assay—most targets configured in Life Technologies fluorescent assay platforms

    Kinase Ordering Table
    Phosphatase Ordering Table

HGNC Alias Select Screen™ profiling status Clinical
Relevance
Drug
Resistance
ABL1 E255K  
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal Tumor Gleevec® (Novartis)
ABL1 G250E  
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal Tumor Gleevec® (Novartis)
ABL1 T315I  
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal Tumor Gleevec® (Novartis)
ABL1 Y253F  
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal Tumor Gleevec® (Novartis)
BRAF V599E  
YES
Melanoma/Papillary Thyroid Carcinoma  
EGFR L858R ErbB1 L858R
YES
Non-Small Cell Lung Carcinoma  
EGFR L861Q ErbB1 L861Q
YES
Non-Small Cell Lung Carcinoma  
EGFR T790M ErbB1 T790M
YES
Non-Small Cell Lung Carcinoma Erlotinib (Tarceva®) and
Gefitinib (Iressa®)
EGFR T790M L858R ErbB1 T790M L858R
NO
Non-Small Cell Lung Carcinoma  
FGFR3 K650E  
YES
Multiple Myeloma, Cervical Carcinoma, Bladder Carcinoma  
FLT3 D835Y  
YES
Acute Myeloid Leukemia  
JAK2 JH1 JH2 V617F  
NO
Myeloid Leukemia, Lymphoid Leukemia  
KIT T670I cKit T670I
YES
Gastrointestinal Stromal Tumor Gleevec® (Novartis)
KIT V654A cKit V654A
NO
Gastrointestinal Stromal Tumor Gleevec® (Novartis)
LRRK2 G2019S  
YES
Parkinson's disease  
LRRK2 G2019S Full Length AURA17, PARK8, RIPK7, ROCO2 YES Parkinson’s Disease  
MAP2K1, mutant MEK1
NO
   
MAP2K6, mutant MKK6, MEK6
NO
   
MET M1250T  
YES
Papillary Renal Carcinoma  
PDGFRA D842V  
YES
Gastrointestinal Stromal Tumor Gleevec® (Novartis)
PDGFRA T674I  
YES
Gastrointestinal stromal tumor Gleevec® (Novartis)
RET Y791F  
YES
Thyroid carcinoma  
RET V804L  
YES
Thyroid carcinoma